Document is current

Article History

Received: 15 July 2021

Accepted: 8 October 2021

First Online: 16 November 2021

Declarations

:

: CD reports grants from Myriad Inc. during the conduct of the study; personal fees from Novartis, personal fees from Roche, personal fees from MSD Oncology, personal fees from Daiichi Sankyo, personal fees from AstraZeneca, from Molecular Health, grants European Commission H2020, grants from German Cancer Aid Translational Oncology, grants from German Breast Group, personal fees from Merck, other from Sividon diagnostics, outside the submitted work; In addition, CD has a patent VMScope digital pathology software with royalties paid, a patent WO2020109570A1—cancer immunotherapy pending, and a patent WO2015114146A1 and WO2010076322A1- therapy response issued. PJ reports stock ownership from Myriad, during the conduct of the study. RK reports personal fees and stock ownership from Myriad, during the conduct of the study; In addition, RK has a patent EP 2553 118 B1 issued, a patent US 13/638,360 pending, and a patent US 62/555,738 pending. WDS reports grants from Myriad Genetics Inc., during the conduct of the study. JUB, JLL, AL, DH, BMP declare that they have no competing interests.

: The diagnostic assessment was performed as part of the clinical routine. The evaluation of existing diagnostic data was performed according to the Berlin hospital law. Ethical approval was given by the ethics committee of Charité Universitätsmedizin Berlin (EA/074/18).

: Not applicable.